Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05197413 · ClinicalTrials.gov registry record · NA
Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms
A NA study of Anxiety and IBS - Irritable Bowel Syndrome, sponsored by Arrae.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT05197413: Completed NA study of Anxiety and IBS - Irritable Bowel Syndrome, sponsored by Arrae.
NCT05197413 is a NA study of Anxiety and IBS - Irritable Bowel Syndrome that has completed, run by Arrae. The registered enrollment target is 35 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05197413, a NA study of Anxiety and IBS - Irritable Bowel Syndrome, has completed, sponsored by Arrae.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label observational crossover trial to study the efficacy of a commercial dietary supplement and its effect on common symptoms of IBS (such as bloating, gas, heartburn, and other symptoms).
Primary Outcome
Survey-based assessment (0-5 scale with 0 being the lowest possible score and 5 being the highest) of changes in IBS symptoms between baseline and study intervention period.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Arrae bloat supplement
Study Locations (1)
California
- Citruslabs - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2021-12-31 |
| Phase | NA |
What the finished NCT05197413 record still lists
NCT05197413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which Arrae bloat supplement is the first listed.
NCT05197413 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05197413 about?
NCT05197413 is a clinical study titled "Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms". This is an open-label observational crossover trial to study the efficacy of a commercial dietary supplement and its effect on common symptoms of IBS (such as bloating, gas, heartburn, and other symptoms).
What is the current status of trial NCT05197413?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2021-09-01. Estimated completion is 2021-12-31.
What conditions does trial NCT05197413 study?
This clinical trial studies the following conditions: Anxiety, IBS - Irritable Bowel Syndrome.
What interventions are being tested in trial NCT05197413?
The interventions under investigation include: Arrae bloat supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05197413?
This trial is sponsored by Arrae, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05197413 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05197413's enrollment target sits among peer trials
35 288th of 364 higher than 73 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
-
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
RECRUITING · NA
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI